Pharmaceutical Industry Marketing
How much does the pharmaceutical industry spend to market its drugs?
Reports of pharmaceutical and medical device industry marketing expenditures vary.
The following are some recent estimates:
• $20.4 billion in 2007 (Verispan)
• $29.8 billion in 2005 (IMS)
• $57.5 billion in 2004 (Gagnon 2008 - CAM and IMS data combined)
• $54 billion in 2001 (Angell 2004 - Extrapolation from Novartis annual reports)
What do these totals include?
Estimates of pharmaceutical marketing normally include detailing, journal advertising, pharmaceutical samples and direct-to-consumer advertising. Detailing is the largest industry marketing segment after expenditures on pharmaceutical samples. It is the industry term for face-to-face sales and promotional activities directed toward office- and hospital-based physicians and directors of pharmacies. It includes pay for sales representatives and the meals and gifts they provide. IMS data includes expenditures to “field the rep” but not the cost of managers and training.
What can be done to protect patients, control health care costs, and bolster professionalism among physicians?
The Prescription Project promotes a range of solutions for consumers, physicians, state and federal policy makers, and public and private payers. For more, visit our website. www.prescriptionproject.org.
Download the full PDF for more information.
- Date added:
- Jan 28, 2009
Pew Comments on Centers for Medicaid and Medicare Services' Information Collection Activities Draft Guidance
The Pew Charitable Trusts appreciates this opportunity to submit comments to CMS's "Information Collection Activities" draft guidance. We suggest that both the research and non-research payment templates be modified in order to make it easier for consumers to identify which drugs, devices, biologicals, or medical supplies are associated with particular transfers of value.More info
One Step Closer to Medical Transparency: Pew's Analysis of the Final Rule for the Physician Payments Sunshine ActOn Feb. 1, 2013, the Centers for Medicare & Medicaid Services published the final rule guiding implementation of the Physician Payments Sunshine Act, which Congress passed as part of the Affordable Care Act in March 2010 to increase transparency in the relationships between physicians and drug and medical device makers. Here are some of the highlights. More info
"The Obama administration issued a new rule this month that requires the makers of prescription drugs and other medical products to disclose what they pay doctors for various purposes, like consulting or speaking on behalf of the manufacturer. This overdue rule adds much-needed weight to previous, more limited disclosure requirements."More info
Allan Coukell, director of medical programs for The Pew Charitable Trusts, issued the following statement in response to the Centers for Medicare & Medicaid Services' final rule for implementing the Physician Payments Sunshine Act, which will bring transparency to the financial relationships between physicians and drug and medical device companies.More info